i-Base home
Search Menu
  • Home
  • HTB
  • Conference reports
  • AIDS 2024: Ten early reports

AIDS 2024: Ten early reports

12 August 2024. Related: Conference reports, Antiretrovirals, World AIDS 25 Munich 2024.

Early reports from the conference will be added below as they are posted.

  • Research to watch out for at AIDS 2024
  • Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more 
  • Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV
  • Five days on two days off: Biktarvy in pilot FOTO study
  • Sub-cutaneous formulation of long-acting CAB/RPV discontinued
  • New community call to challenge social settings that drive HIV-related stigma
  • UNAIDS report: The urgency of now – AIDS at a crossroads.
  • Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study

Links to other websites are current at date of posting but not maintained.

  • HTB RSS
  • BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024
  • WHO declares new mpox emergency (clade 1b): tecovirimat not effective in DRC study

Early access

  • Vaccination effectively limits mpox progression: lower efficacy in people living with HIV 27 May 2025
  • US update guidelines for statin use in people living with HIV 26 May 2025
  • HIV activists in the US call for action and Zachie Achmet brings South African perspective 26 May 2025
  • Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement 22 May 2025
  • All early access reports

Current issues

  • May 2025
  • April 2025
  • March 2025
  • Back issues

Special report

  • Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement 22 May 2025

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage
  • Donate

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
Registered charity number: 1081905. Company number: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Donate
Feedback
Advice and information
Q and A
Guides
HIV meds
Glossary
Research reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
News and updates
Sitemap
Home
Find us on Facebook
i-Base on Facebook